Definitive Contract HHSN261201300042C
Award Date 9/20/13
Potential Completion Date 7/18/14
Potential Value $252K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
MONTGOMRY VLG, MD 20877, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
23
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a "fibrous scaffold-induced spheroids mimicking TME" solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>
- <p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
- This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the "SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM" and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian federal agency, to Ilsbio LLC, a for-profit limited liability company. The contract is for the recovery of tissue samples and data from various types of cancer to support the Cancer Genome Atlas (TCGA) program. This award is part of the NCI Cancer Genome Atlas Program Tissue Purchase master IDIQ contract and is funded under the American Recovery and Reinvestment Act (ARRA). The contract has a...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
- This is a $225,000.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a Minority Owned, For Profit, Subcontinent Asian (Asian-Indian) American Owned business. The contract is for "SBIR PHASE I - FISS-CSC: A FIBER-INSPIRED SMART SCAFFOLD PLATFORM FOR EXPANDING CANCER STEM CELLS" and was awarded on September 22, 2015 with a completion date of August 21, 2016. This appears to be a Small Business Innovation Research...
- <p>The National Cancer Institute awarded a $224,999.00 Firm Fixed Price definitive contract to Transgenex Nanobiotech Inc., a minority-owned for-profit business, to develop anti-NPRA inhibitors targeting cancer stem cells in tumoroids. The contract has a completion date of September 11, 2015 and is not associated with any set-aside designation. Transgenex Nanobiotech Inc. has received previous federal contract and grant awards, with the most recent contract award on February 1, 2017.</p>
- This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute (NCI) to Inlighta Biosciences L.L.C., a woman-owned small business. The $298,230.00 firm fixed-price contract is for a Phase I Small Business Innovation Research (SBIR) project titled "Non-Invasive Subtyping of Aggressive Tumor and Its Environment" as part of the NCI Cancer Moonshot initiative. The original solicitation was issued under the NIH/CDC...
- This federal contract award, HHSN261201000135C, was issued by the National Cancer Institute, a civilian agency, to the small business prime contractor 20 / 20 Genesystems, Inc. (doing business as 20 / 20 Genomics). The award has a ceiling value of $182,576.00 and is a definitive, firm-fixed-price contract with a completion date of November 29, 2011. The contract is set aside for small businesses. The work to be performed under this contract is described in the solicitation as "TAS::75...